Skip to main content

This website is not compatible with Internet Explorer. If you are experiencing difficulties, please try a different Internet browser (Chrome, Firefox, Edge or Safari).

Many of the drug classes which are included in the prior authorization program are reviewed each fiscal year.  These reports include detailed statistics on utilization, prior authorization, market share, new products, and other notable events for the category during the previous year.  These reports were not included on a DUR Board agenda and are in addition to the utilization reports included with the DUR Board packets.

 

2009

FAD 

Forteo 

Symlim 

Xolair 

 

Last Modified on Nov 10, 2020
Back to Top